Viridian Therapeutics Inc... (VRDN)
Viridian Therapeutics Inc. (VRDN) Stock Price, Analysis & Data
| Bid | 17 |
| Market Cap | 2.81B |
| Revenue (ttm) | 71.13M |
| Net Income (ttm) | -334.03M |
| Beta | 0.94 |
| EPS (ttm) | -3.4 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.94 |
| P/B (ttm) | 5.04 |
| P/S (ttm) | 39.50 |
| Earnings Date | Nov 5, 2026 |
| Ask | 29.45 |
| Volume | 1,992,362 |
| Avg. Volume (20D) | 2,038,337 |
| Open | 23.00 |
| Previous Close | 23.09 |
| Day's Range | 22.84 - 23.95 |
| 52-Week Range | 13.18 - 34.29 |
| Analyst | Strong Buy |
| Price Target | 35.5 (48.35%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VRDN
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TS...
Financial Performance
In 2025, Viridian Therapeutics's revenue was 70.85M, an increase of 23,359.93% compared to the previous year's 302K. Earnings were -342.6M, an increase of 26.91%.
Financial StatementsAnalyst Forecast
According to 16 analyst ratings, the average rating for VRDN stock is "Strong Buy". The 12-month stock price forecast is 35.5, which is upside of 48.35% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
